Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.

摘要: In the EORTC-ISG-AGITG trial 946 patients with advanced gastro-intestinal stromal tumours (GIST) were randomised to receive 400 or 800 mg of imatinib daily. An increase in progression free survival (PFS) was demonstrated for high-dose arm. Patients low-dose could cross-over upon progression. We evaluated feasibility, safety and efficacy this policy. Of 241 available follow-up, 133 (55%) crossed over according protocol. these patients, 92% had not a prior dose reduction. The cumulative incidence subsequent reductions after 17% six months 51% discontinuing therapy without requiring extent anaemia fatigue increased significantly cross-over, whilst neutropenia less severe than during treatment. Objective responses included three (2%) partial response 36 (27%) stable disease. median PFS 81 days, although 18.1% still alive one year cross-over. conclude that is feasible safe GIST who progress on therapy.